Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on December 3, 2019, covering events occurring on December 2, 2019. The company is a Delaware corporation with its principal executive offices in Florham Park, New Jersey. Its common stock (CLRB) and warrants (CLRBZ) trade on the NASDAQ Capital Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event rather than a periodic financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing serves to disclose a regulatory communication regarding an upcoming scientific presentation.
Guidance, Outlook, and Management Commentary
On December 2, 2019, the company issued a press release announcing an oral presentation at the 61st Annual American Society of Hematology (ASH) meeting. The conference is scheduled to take place from December 7-10, 2019, in Orlando, Florida. The full text of the press release is included as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the content and data presented at the 61st Annual ASH meeting (December 7-10, 2019) referenced in the press release.
- Review Exhibit 99.1 for specific details regarding the oral presentation.
- Confirm the company's status as an emerging growth company, as indicated by the check mark in the filing.